About the Infographic
Through comprehensive data analysis, Beacon has identified 175 assets for LSDs, accounting for 8% of our database. Most of these assets are still preclinical and use classical gene therapies. We have observed that adeno-associated viruses (AAV) are the most common delivery systems used, with AAV9 being the second most common serotype leveraged due to its unique targeting capabilities.
Our analysis also revealed that most genes targeted by LSD assets are lysosomal or responsible for breaking down large carbohydrates. Large pharmaceutical companies dominate the developer landscape for LSDs due to the considerable amount of money required to translate research into clinical trials. Join us as we explore the landscape of LSD research and development.
Speak with our Team
At Beacon, we are committed to empowering our pharmaceutical and biotech industry partners with accurate, comprehensive data. We are not just a tool; we see ourselves as a partner in the drug development journey. Contact us to learn how we help you.
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies and the most accurate and comprehensive life sciences data provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements.